logo Hematology/Oncology Research Studies: Open for Enrollment Date: 05/27/20


Phase 2 Study of everolimus for recurrent or progression low-grade gliomas in children

NCT#/Phase: NCT01734512
Phase 2
IRB#: 2013-027
Description: This is an open label study of everolimus in children with recurrent or progressive low-grade glioma. All patients will receive everolimus at a dose of 5 mg/m2/dose daily.
Inclusion: Individuals who are between 3 - 21 years of age with refractory, progressive or recurrent low-grade glioma (WHO grade I or II), confirmed histologically at diagnosis.
Enrollment Status: Open for enrollment
Sponsor: Pacific Pediatric Neuro-Oncology Consortium (PNOC)
Principal Investigator(s): Caroline Hastings, MD
Contact(s): Caroline Hastings, MD

Study Link: https://clinicaltrials.gov/ct2/show/NCT01734512

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 &bull Phone: (510) 428-3000